



Investor Service Announcement no. 3/2009

To: NASDAQ OMX Copenhagen

Hørsholm, Denmark, May 9, 2009

**LifeCycle Pharma A/S to Host Conference Call Announcing
Interim Report for 1st Quarter 2009 – results from January 1 to March 31, 2009**

LifeCycle Pharma A/S (OMX: LCP) will announce the Interim Report for 1st Quarter 2009 on Thursday May 14, 2009. LCP's Executive Management will host an accompanying conference call to discuss the financial results on Thursday May 14, 2009 at 15:00 CET (Denmark); 14:00 GMT (London), 09:00 AM ET (New York), 06:00 AM PT (San Francisco).

To access the live conference call, please dial one of the following numbers:

+1 866 966 5335 (US)

+44 2030 032 666 (UK)

+45 8088 8649 (DK)

An audio replay of the conference call will be available on www.lcpharma.com from Thursday, May 14, 2009 at 18:00 CET (Denmark); 17:00 GMT (London), 12:00 PM ET (New York), 09:00 AM PT (San Francisco), through Friday, June 12, 2009 by dialing +44 2081 961 998 (UK) or +1 866 583 1035 (US), and entering access code 8403 264#.

For more information, please contact:

Dr. Jim New

President & Chief Executive Officer

Phone: + 45 7033 3300

Email: JSN@lcpharma.com

or

Peter Schøtt Knudsen

Head of Investor Relations

Phone: + 45 2055 3817

Email: PSK@lcpharma.com

About LifeCycle Pharma A/S (LCP)

Based in Hørsholm, Denmark, with an office in New York, LCP is an emerging specialty pharmaceutical company. Clinical development is the core of LCP's effort to develop a product portfolio which includes products for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. As a fully integrated company, LCP adapts new technologies on a fast commercial timetable. LCP's unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability – at low-scale up costs – not only for a broad spectrum of drugs already on the market but also for new chemical entities. LCP has a cholesterol-lowering product, Fenoglide®, currently on the U.S. market and a diversified near- and medium-term pipeline with four product candidates in clinical trials and a number of projects in preclinical development. LCP is listed on the NASDAQ OMX Copenhagen under the trading symbol (OMX: LCP).

For further information, please visit www.lcpharma.com.

LifeCycle Pharma A/S
Kogle Allé 4
DK-2970 Hørsholm
CVR no. 26 52 77 67

Investor Service Announcement no. 3/2009